Adarigiline
Overview of the drug Adarigiline
| Adarigiline | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Adarigiline is a monoamine oxidase inhibitor (MAOI) that has been investigated for its potential use in the treatment of neurodegenerative disorders, particularly Parkinson's disease. It is a selective and irreversible inhibitor of the enzyme monoamine oxidase B (MAO-B), which is involved in the breakdown of dopamine in the brain.
Mechanism of Action[edit | edit source]
Adarigiline functions by inhibiting the activity of MAO-B, an enzyme that degrades dopamine. By preventing the breakdown of dopamine, adarigiline increases the availability of this neurotransmitter in the central nervous system. This action is particularly beneficial in conditions like Parkinson's disease, where dopamine levels are critically low.
Pharmacokinetics[edit | edit source]
Adarigiline is administered orally and is well absorbed from the gastrointestinal tract. It undergoes extensive metabolism in the liver, primarily through the action of cytochrome P450 enzymes. The metabolites are excreted via the kidneys.
Clinical Applications[edit | edit source]
Adarigiline has been primarily studied for its potential use in treating Parkinson's disease. By increasing dopamine levels, it may help alleviate symptoms such as bradykinesia, rigidity, and tremor. However, as of the latest updates, adarigiline has not been approved for clinical use and remains an investigational drug.
Side Effects[edit | edit source]
The side effects of adarigiline are similar to those of other MAO-B inhibitors and may include nausea, dizziness, insomnia, and headache. Due to its mechanism of action, there is also a risk of hypertensive crisis if taken with tyramine-rich foods or certain medications.
Research and Development[edit | edit source]
Research on adarigiline has focused on its neuroprotective properties, with studies suggesting it may help slow the progression of neurodegenerative diseases. However, further clinical trials are necessary to fully understand its efficacy and safety profile.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
